Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy.

Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. Curr Med Res Opin. 2019 Dec 21;:1 Authors: Lapolla A, Genovese S, Giorgino F, Disoteo O, Sartore G, Bartezaghi M, Del Prato S Abstract Objective: To assess patient-reported outcomes after two years of use of dual oral anti-diabetes drug (OAD) therapy in elderly people (≥65 years) with type 2 diabetes mellitus (T2DM) from Italy under real-life settings.Methods: 3-AGE was a prospective, non-interventional study in elderly people with T2DM inadequately controlled on metformin monotherapy (defined as glycated hemoglobin [HbA1c] 7.0%-9.0%), in whom a second OAD was prescribed. Primary endpoint was to assess the physical and psychological symptoms associated with T2DM from baseline to 24 months using the Diabetes Symptom Check List revised (DSC-R) questionnaire. Patient's quality of life and health status, treatment satisfaction, consumption of healthcare resources, and physician satisfaction with treatment were also assessed (secondary endpoints) using validated questionnaires. Additionally, safety and clinical characteristics were also evaluated.Results: The mean age of the study population (N = 860) was 71.5 ± 5.2 years. Addition of a second OAD significantly (p 
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research

Related Links:

Condition:   Type-2 Diabetes Intervention:   Procedure: Aerobic Exercise Sponsor:   Emresenocak Completed
Source: - Category: Research Source Type: clinical trials
Authors: Ishida Y, Murayama H, Shinfuku Y, Taniguchi T, Sasajima T, Oyama N Abstract Objectives: The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin is indicated for type 2 diabetes mellitus (T2DM). However, the long-term safety, effectiveness, and clinical relationship with cardiovascular events of vildagliptin have not been evaluated in Japan.Methods: The authors conducted post-marketing surveillance (PMS) to evaluate the safety and effectiveness of vildagliptin in more than 3000 Japanese T2DM patients for up to 3 years. Main assessments included demographics, major adverse cardiovascular events (MACE)...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research
Diabetes mellitus (DM) and chronic kidney disease (CKD) significantly increase the risk of cardiovascular morbidity and mortality. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a new class of hypoglycemic agents that have shown significant promise in the reduction of cardiovascular events. Current guideline recommendations do not support the use of these agents in patients with CKD stage 3 or higher. We performed a comprehensive meta-analysis to evaluate their cardiovascular effects in patients with type 2 DM and CKD stage 3 or higher. A comprehensive search was performed in PubMed, Cochrane central, and Embase. S...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research
Publication date: June 2020Source: Cancer Epidemiology, Volume 66Author(s): Wayne R. Lawrence, Akiko S. Hosler, Margaret Gates Kuliszewski, Matthew C. Leinung, Xiuling Zhang, Maria J. Schymura, Francis P. Boscoe
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
AbstractRegulatory T cells (Tregs) play an immunosuppressive role in various diseases, yet their function remains controversial in stroke and obscure in diabetic stroke. In the present study, Tregs were found downregulated in the peripheral blood of type 2 diabetes mellitus (T2DM) stroke models and patients compared with controls. In ischemic stroke mice (both T2DM and wild type), endogenous Tregs boosted by CD28SA increased CD206+ M2 macrophage/microglia cells, decreased infarct volumes, and improved neurological recovery. Our results demonstrated the potential of boosting Tregs for treating T2DM stroke. Furthermore, we u...
Source: Translational Stroke Research - Category: Neurology Source Type: research
In conclusion, the protective effect of HDL to counter ER stress and β-cell death involves the transport, generation, and mobilization of oxysterols for activation of the Hh signaling receptor SMO
Source: The Journal of Lipid Research - Category: Lipidology Authors: Tags: Research Articles Source Type: research
Nutrition &Diabetes, Published online: 01 April 2020; doi:10.1038/s41387-020-0111-zAssociations between cognitive performance and Mediterranean dietary pattern in patients with type 1 or type 2 diabetes mellitus
Source: Nutrition and Diabetes - Category: Nutrition Authors: Source Type: research
As recently summarized1, there are only four randomized clinical trials (RCTs) in patients with type 2 diabetes mellitus (T2DM) comparing Roux-en-Y gastric bypass (RYGB) with sleeve gastrectomy (SG) and providing level I evidence up to 5 years after randomization.2-5 None of the individual studies were primarily designed and adequately powered to compare the effects of RYGB with SG on T2DM. However, combined analysis of these RCTs (i.e. meta-analysis) in order to increase the sample size and statistical power (RYGB, n=176 versus SG, n=175) would indicate that either there is no significant long-term difference between RYGB...
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Letter to the Editor Source Type: research
This study was conducted among 160 diabetic patients with NAFLD proven biopsy. Anthropometric assessments, laboratory test, liver histological features and follow-up of a Mediterranean diet were evaluated.ResultsDiabetic patients with liver fibrosis showed a greater number of positive metabolic criteria than diabetic patients without liver fibrosis. Patients with hepatic fibrosis have a lower score on the PREDIMED test (9.0 (2.4) vs. 6.2 (2.3);p 
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Endocrinology | Fortamet | Italy Health | Metformin | Psychology | Research | Study